The National Kidney Foundation (NKF) recently exhibited a worldwide report intended to comprehend the experimental immunosuppressant drug Voclosporin as a possible treatment for patients suffering from lupus kidney disease.
Lupus nephritis refers to the inflammation of kidneys caused by systemic lupus erythematous (SLE). Also known as lupus, SLE is an autoimmune disease where the body’s immune system starts targeting the body’s own cells. Around 60% of the lupus patients develop lupus nephritis. If not controlled properly, it can lead to kidney failure. The major symptoms of the disease include:
- Weight gain
- High Blood pressure
- Dark urine
- Frothy urine
- Excessive need to urinate
The revolutionary investigation, “AURORA Phase 3 Trial Demonstrates Voclosporin Statistical Superiority Over Standard of Care in Lupus Nephritis (LN)” was chosen as a ‘late-breaking poster presentation’ browsed among many different disclosures and presented at the establishment’s yearly Spring Clinical Meetings.
Aurora is a ‘global study’ intended to assist the researchers in comprehending if adding voclosporin to mycophenolate mofetil (MMF) and steroids, regular medicines for lupus kidney infection, will improve results and prove effective in patients with dynamic lupus kidney disease.
According to Keisha L. Gibson, lead investigator and Associate Professor of Medicine and Pediatrics, DOM Vice Chair of Diversity and Inclusion Chief, Pediatric Nephrology, UNC Kidney Center, “We are pleased to report that the patients who received voclosporin were 2.65 times more likely to meet the criteria for response based on proteinuria and eGFR. There were no differences in the safety profile between the voclosporin and standard care groups. We know that achieving remission status in lupus kidney disease correlates with good long-term kidney survival and so the results of this study are very encouraging”
In light of the aftereffects of this study, Aurinia is currently arranging to file an application with the FDA for endorsement, which whenever affirmed, will open access to this medicine to patients with the disease. Meanwhile, as per Dr. Gibson, numerous members that took part in the study will turn over into a 2-year expansion.
There are a series of Spring Clinical Meetings held every year. This year, however, they are ‘Live virtual interactions’, given the ongoing Coronavirus outbreak. These measures will ensure safety of the patients, workers and the volunteers.
About NKF Spring Clinical Meetings
For as far back as 28 years, nephrology healthcare experts from across the nation over have gone to NKF’s Spring Clinical Meetings to find out about the most up to date improvements identified with all parts of nephrology practice; coordinate with partners; and present their examination discoveries.
“The NKF Spring Clinical Meetings are designed for meaningful change in the multidisciplinary healthcare teams’ skills, performance, and patient health outcomes.”
Healthcare experts can join NKF to get access to apparatuses and resources for the patients and professionals, discounts on professional training, and access to a system of thousands of people who treat patients with kidney malfunction.
Kidney Disease Facts
- In the United States, 37 million grown-ups are evaluated to have chronic kidney disease.
- One out of every 3 American grown-ups are in danger for chronic kidney disease.
- Risk factors for kidney diseases incorporate diabetes, hypertension, coronary illness, obesity and family ancestry.
- Individuals of African American, Hispanic, Native American, Asian or Pacific Islander plummet are at an expanded risk of developing a kidney disease.
- African Americans are three times more probable than Whites, and Hispanics are about 1.5 times more likely than non-Hispanics to get diagnosed with end-stage renal disease.
About National Kidney Foundation (NFK):
The National Kidney Foundation (NKF) is the biggest, generally extensive, and longstanding patient-driven association devoted to the mindfulness, avoidance, and treatment of kidney diseases in the U.S.